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Hemoglobin A1c (HbA1c) is recommended for diagnosing and monitoring diabetes. How-
ever, in people with sickle cell disease (SCD), sickle cell trait (SCT), α-thalassemia or glu-
cose-6-phosphate dehydrogenase (G6PD) deficiency, HbA1c may underestimate the
prevalence of diabetes. There are no data on the extent of this problem in sub-Saharan
Africa despite having high prevalence of these red blood cell disorders.
Methods
Blood samples from 431 adults in northwestern Tanzania, randomly selected from the pro-
spective cohort study, Chronic Infections, Comorbidities and Diabetes in Africa (CICADA),
were analysed for SCT/SCD, α-thalassemia and G6PD deficiency and tested for associa-
tions with the combined prevalence of prediabetes and diabetes (PD/DM) by HbA1c, using
the HemoCue 501 HbA1c instrument, and by 2-hour oral glucose tolerance test (OGTT).
Results
The mean age of the participants was 40.5 (SD11.6) years; 61% were females and 71%
were HIV-infected. Among 431 participants, 110 (25.5%) had SCT and none had SCD. Het-
erozygous α-thalassemia (heterozygous α+ AT) was present in 186 (43%) of the partici-
pants, while 52 participants (12%) had homozygous α-thalassemia (homozygous α+ AT).
Furthermore, 40 (9.3%) participants, all females, had heterozygous G6PD deficiency while
24 (5.6%) males and 4 (0.9%) females had hemizygous and homozygous G6PD deficiency,
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respectively. In adjusted analysis, participants with SCT were 85% less likely to be diag-
nosed with PD/DM by HbA1c compared to those without SCT (OR = 0.15, 95% CI: 0.08,
0.26, P < 0.001). When using OGTT, in adjusted analysis, SCT was not associated with
diagnosis of PD/DM while participants with homozygous α+ AT and hemizygous G6PD defi-
ciency were more likely to be diagnosed with PD/DM.
Conclusions
HbA1c underestimates the prevalence of PD/DM among Tanzanian adults with SCT. Fur-
ther research using other HbA1c instruments is needed to optimize HbA1c use among pop-
ulations with high prevalence of hemoglobinopathies or G6PD deficiency.
Introduction
Diabetes is becoming a major cause of morbidity and mortality in low-and middle-income
countries [1]. Traditionally, diagnostics relied on random or fasting blood glucose with or
without an oral glucose tolerance test (OGTT) [2]. However, OGTT testing is laborious and
both OGTT and fasting plasma glucose have significant daily variability. The World Health
Organization (WHO) has approved the use of glycated hemoglobin (HbA1c) as a universal
diabetes test [3], as HbA1c has several advantages over OGTT: fasting is not needed, measure-
ment is less laborious, and it estimates long-term average plasma glucose. WHO approval led
to increased adoption of HbA1c for diagnosing and managing diabetes globally, including in
low-and middle-income countries.
Although current assay instruments have removed many technical problems associated
with the estimation of HbA1c, several challenges remain [4]. These include diagnosis and
management of diabetes in patients with altered hemoglobin structure, e.g., SCD/SCT or α-
thalassemia, or an enzymopathy such as G6PD deficiency.
Hemoglobin A (HbA) represents over 90% of hemoglobin in healthy red blood cells (RBCs)
among normal individuals, but individuals with SCT have 30–40% as hemoglobin S (HbS)
[5,6]. The presence of HbS may be associated with shorter RBC life span [7], which may reduce
the time for hemoglobin glycation, leading to underestimation of glucose level by HbA1c tests.
Few studies have investigated the suitability of HbA1c in diabetes diagnosis among individuals
with SCD/SCT and results have been inconsistent. Two studies among African Americans
found that SCT did not affect the validity of HbA1c as a diagnostic test for diabetes [6,8], while
a larger cohort study showed that compared to fasting blood glucose and OGTT, HbA1c pro-
duced lower glucose equivalent estimations in individuals with SCT than in those without SCT
[9].
Thalassemia is an inherited hemolytic blood disorder that involves underproduction or
absence of synthesis of one or more globin chains of hemoglobin. The disorder causes hemoly-
sis, leading to shorter RBC life span [10], resulting in a short exposure time to glucose. How-
ever, the use of HbA1c in populations with a high prevalence of thalassemia has been reported
to give false high diabetes prevalence estimates as compared with other diabetes tests [11]. The
two main types of thalassemia are α-thalassemia and β-thalassemia. In this study we focused
on α-thalassemia because of its higher prevalence in Tanzania (37.8% heterozygous α+ AT and
5.2% homozygous α+ AT) [12] compared to β-thalassemia (0.2%) [13].
G6PD deficiency, which is common in people of Mediterranean and African origin includ-
ing Tanzania [12], also predisposes RBCs to hemolysis [14] and reduces the exposure time of
hemoglobin to glucose, resulting in falsely low HbA1c levels [15,16].
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There are no published reports from sub-Saharan Africa on the validity of HbA1c in popu-
lations with hemoglobinopathies and G6PD deficiency, although the conditions are common.
Recent studies in Tanzania found prevalence of 1.4% SCD, 15.9% to 19.7% SCT, 37.8% hetero-
zygous α+ AT, 5.2% homozygous α+ AT, and 29.9% for combined heterozygous (G6PD(A))
and homozygous/hemizygous (G6PD(A-)) G6PD deficiency [12,13]. Given the high preva-
lence of disorders affecting red blood cells in Tanzania, we aimed to investigate the associa-
tions of SCT/SCD, α-thalassemia and G6PD deficiency with diagnosis of diabetes using
HbA1c WHO thresholds.
We hypothesized that HbA1c tests estimate lower prevalence of PD/DM in people with
SCT, α-thalassemia and G6PD deficiency than in people without these abnormalities, poten-
tially compromising the test’s validity in these populations.
Methods
Ethical considerations
CICADA, including the current study procedures, received ethical approval from the Medical
Research Coordinating Committee (MRCC) of the National Institute for Medical Research
(NIMR) in Tanzania, from the London School of Hygiene and Tropical Medicine, and consul-
tative approval from the National Committee on Health Research Ethics in Denmark. Oral
and written information on study objectives, procedures, benefits, risks, confidentiality, and
voluntary participation was provided in Swahili language. Participants’ approval to use their
confidential information and stored samples, e.g., blood for the future studies, was also part of
the provided information. They were also offered opportunity to ask questions which were
answered to their satisfaction before they were asked to sign informed consent forms. For par-
ticipants who could not read and write, solicited witnesses who were not part of the study
team signed informed consent forms on their behalf.
Study design, setting and study population
This was a cross-sectional sub-study embedded in the ongoing prospective cohort study,
Chronic Infections, Comorbidities and Diabetes in Africa (CICADA), which is investigating
risk factors for diabetes in adults with and without HIV (trial registration NCT03106480).
CICADA enrolled 1,947 adults aged� 18 years with HIV who were antiretroviral therapy
(ART)-naïve, as well as ART-experienced and HIV-uninfected control participants from
Mwanza, Tanzania between October 2016 and October 2017 (17). Stored blood samples col-
lected at enrollment in CICADA were used for the current study. All CICADA participants
with a stored blood sample were eligible for inclusion in this sub-study; 500 samples were
selected using the simple random sampling method after assigning each participant with a ran-
dom number using Microsoft Excel 2007.
Data collection
Electronic and paper-based questionnaire data were used to gather information at enrollment
into CICADA. Information on demography and socioeconomic status was gathered using the
WHO STEPS questionnaire and show cards [17]. Socioeconomic status, categorised as terciles,
was derived using principal components analysis based on housing characteristics, sanitation,
water source, cooking fuel, ownership of electrical goods and animals, and modes of transport.
Reported alcohol intake was classified as current use (within 12 months) or non-use (previous
or never used), while reported smoking was classified as never, past, or currently smoking.
HIV status (defined as either HIV-negative, HIV-infected/not on ART, or HIV-infected/on
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ART) and ART history was verified through participants’ ART cards and clinic records. Data
for SCT/SCD, α-thalassemia and G6PD deficiency for this sub-study were filled in the labora-
tory results form and entered in Epidata.
Anthropometry
Trained study staff assessed weight to the nearest 0.1 kg using a digital scale (Seca, Germany),
and height was measured to the nearest 0.1 cm using a stadiometer fixed to the clinic wall
(Seca, Germany). Anthropometric measurements were taken in triplicate, and medians were
used for analysis. Body mass index (BMI) was calculated as weight (kg)/(height (m))2 and clas-
sified as underweight/normal (� 24.9 kg/m2) or overweight/obese (� 25.0 kg/m2) [18].
Diabetes-related measurements
Symptoms of diabetes were solicited and recorded. Venous blood for HbA1c was drawn from
those who had fasted, and participants were then given 82.5 g of dextrose monohydrate (equiv-
alent to 75 g of anhydrous glucose) diluted in 250 ml of drinking water to drink within 5 min-
utes for OGTT. Blood for OGTT glucose was collected after 30 minutes and 2 hours, and
glucose was measured with a point-of-care machine (HemoCue 201RT, Ängelholm, Sweden)
[19]. HbA1c was measured with a point-of-care device (HemoCue HbA1c 501), which uses a
boronate affinity assay to separate the glycated hemoglobin fraction from the non-glycated
fraction; the instrument is calibrated to harmonize with HPLC method (HbA1c 501 Analyzer,
Operating Manual).
Test results were grouped into three levels–normal, prediabetes, and diabetes using thresh-
olds recommended by WHO [2,3]. For HbA1c, prediabetes was defined as 6.0% to< 6.5% and
diabetes was defined as� 6.5%; levels below 6.0% were considered normal. For OGTT, 2-hour
glucose levels between 7.8 and 11.1 mmol/L were defined as prediabetes and� 11.1 mmol/L
indicated diabetes; levels < 7.8 mmol/L were considered normal. Prediabetes and diabetes
results were then combined as one outcome, PD/DM.
Hemoglobin assessment
Hemoglobin (Hb) levels (g/dl) were measured using a Beckman Coulter AcT5 diff AL Hema-
tology Analyzer (Beckman Coulter, Florida, USA) and classified as anemic if Hb was� 12 g/dl
for females or� 13 g/dl for males [20].
DNA extraction and genotyping
Blood samples were collected in 5 ml EDTA tubes and stored at -80˚C until tested. DNA was
extracted from whole blood using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany)
according to manufacturer’s instructions. Polymerase chain reaction (PCR) and genotyping
procedures for the α-thalassemia, 3.7 kb deletion was done as previously described [21], with
one forward primer 3.7F (50-AAGTCCACCCCTTCCTTCCTCACC-30) and two reverse primers,
3.7R1 (50-ATGAGAGAAATGTTCTGGCACCTGCACTTG-30) and 3.7R2 (50-ATCCCCTCCTCC
CGCCCCTGCCTTTTC-30). PCR products with 2,213 bp were assigned as no α-thalassemia and
those with 1,963 bp as homozygous α+ AT. Products with 2,213 bp and 1963 bp were assigned
as heterozygous α+ AT. The PCR and genotyping characterization of G6PD deficiency was
done as previously described [22], using forward primer (50-CTGGCCAAGAAGAAGATCTAC
CC-30) and reverse primer (50-GAGAAAACGCAGCAGAGCACAG 30). The restriction fragment
length polymorphism (RFLP) products with 300 bp and 180 bp were assigned as normal, 180
bp and 120 bp were assigned as homozygotes female/hemizygous male, and 300 bp, 180 bp,
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and 120 bp were termed as heterozygotes. Hemoglobin sub typing for SCT/SCD was per-
formed by PCR RFLP and gel electrophoresis as explained by Modiano [23]. In the first round
of RFLP with MnII reactions, products with 173 bp, 109 bp, and 60 bp were assigned as HbAA,
ambiguous products with 173 bp, 109 bp, and 76 bp were assigned as HbCC/SS/SC and those
with 173 bp, 109 bp, 76bp, and 60 bp were assigned as HbAC/AS. In a second round of RFLP
with DdeI reaction to resolve ambiguities from the first round, products with 331 bp were
assigned as HbSS, and those with 130 bp, 201 bp, and 331 bp were assigned as HbAS.
Sample size and power considerations
The study was exploratory and had funds to obtain hemoglobinopathy information only on a
sub-set of CICADA participants. In the entire CICADA cohort, diabetes was diagnosed using
HbA1c in 13% of participants, and an additional 17% were pre-diabetic [19]. Assuming a
higher prevalence of PD/DM among participants without hemoglobinopathies of 32%, with
80% statistical power, the study could detect PD/DM among participants with hemoglobinop-
athies of 19%, with at least 80% power.
Data analysis
Data were analysed in STATA version 13 (StataCorp, College Station, Texas, USA). Descrip-
tive analysis was done using histograms for shape distributions. Differences between paramet-
ric continuous variables were compared using t-test and one-way ANOVA, while non-
parametric variables were compared using Kruskal Wallis test. Chi-square tests were used to
compare categorical variables. The primary outcomes were PD/DM by (1) HbA1c and (2)
OGTT. The main exposures were (1) SCT/SCD, (2) α-thalassemia and (3) G6PD deficiency.
Logistic regression was used to examine associations of these exposures with PD/DM diagnosis
by HbA1c and OGTT. Factors identified with p< 0.2 in univariable analysis were included in
multivariable models.
For each hemoglobinopathy the comparison group comprised participants without that
specific trait, even though they may have had one or both of the other traits investigated. Other
factors considered in models were categorized age, sex, BMI, socioeconomic status, HIV sta-
tus, alcohol use, smoking status, and hemoglobin level.
Non-parametric receiver operating characteristic (ROC) analysis was used to calculate the
area under the ROC curves (AUROC), sensitivity and specificity. The calculated AUROC, sen-
sitivity and specificity were used to assess the discriminative ability of HbA1c to identify the
combined presence of PD/DM defined by the gold standard 2-hour OGTT. We present results
stratified by SCT status.
Because there is evidence that both HIV infection and ART are associated with diabetes
[24], interactions between HIV status and SCT, α-thalassemia, and G6PD deficiency in rela-
tion to PD/DM diagnosis by both HbA1c and OGTT were explored.
Sensitivity analysis was also considered for the final multivariable models using two meth-
ods: logistic regression models where those with other hemoglobinopathies were removed
from the comparison group and multinomial regression with no diabetes as the reference and
compared separately to the prediabetes and diabetes groups.
Results
Participant characteristics and hemoglobin variants
CICADA recruited 1947 participants in 2016–2017; among them, PD/DM was diagnosed in
582/1944 (29.9%) by HbA1c and in 972/1941 (50.1%) by OGTT. We randomly selected 500/
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1947 (26%) participants from the total CICADA cohort for inclusion in this sub-study. After
excluding 25/500 (5.0%) samples that lacked concurrent HbA1c and 2-hour OGTT measure-
ments and 44/500 (8.8%) samples with unsuccessful genotyping due to poor quality/quantity
of extracted DNA or poor visualisation of DNA bands on agarose gel (Fig 1), we analysed 431/
500 (86.2%) of the randomly selected participants.
The mean age of included participants was 40.5 (SD11.6) years; 261/431 (61%) were female.
Most participants, 306/431 (71%) were living with HIV: 79/306 (26%) were established on
ART and 227/306 (74%) not yet on ART (Table 1). Characteristics of sub-study participants
were similar to those not included (S1 Table). SCT (HbAS) was found in 110/431 (25.5%)
Fig 1. Participant enrollment and inclusion in analysis.
https://doi.org/10.1371/journal.pone.0244782.g001
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participants; no participants had SCD. Heterozygous and homozygous α+ AT were found in
186/431 (43.1%) and 52/431 (12.1%), respectively (Table 1). G6PD deficiency was the least
common of the traits investigated: 40/431 (9.3%) were female heterozygotes (G6PD(A)), while
24/431 (5.6%) males and 4/431 (0.9%) females were hemizygotes and homozygotes (G6PD(A-
)), respectively.
The most prevalent combinations were SCT plus heterozygous α+ AT without G6PD defi-
ciency (HbAS, heterozygous α+ AT, G6PD(B)) in 41/431 (10.2%), followed by heterozygous α+
AT plus heterozygous G6PD deficiency without SCT (HbAA, heterozygous α+ AT, G6PD(A))
in 18/431 (4.2%) and SCT plus homozygous α+ AT without G6PD deficiency (HbAS, homozy-
gous α+ AT, G6PD(B)) in 11/431 (2.6%) (Table 2).
Overall, 92/431 (21.4%) participants were diagnosed with PD/DM by HbA1c only; among
them, 9/92 (9.8%) had SCT. By OGTT only, 103/431 (23.9%) had PD/DM and 47/103 (45.6%)
of these had SCT. By both HbA1c and OGTT, 108/431 (25.1%) participants were diagnosed
with PD/DM; of these 13/108 (12.0%) had SCT.
Table 1. Background characteristics of the study population.
Characteristic n = 431
Age, mean (SD), years 40.5 (11.6)
Female, n (%) 261 (60.6)




Body mass index, mean (SD), (kg/m2) 21.9 (4.5)
Hemoglobin, mean (SD), (g/dl) 12.3 (2.4)
HIV status, n (%)
HIV-negative 125 (29.0)
HIV-positive not on ART 227 (52.7)
HIV-positive on ART 79 (18.3)
Sickle cell, n (%)
Normal (HbAA) 321 (74.5)
Sickle cell trait (HbAS) 110 (25.5)
Sickle cell disease (HbSS) 0 (0.0)
α-thalassemia, n (%)
No thalassemia 193 (44.8)
Homozygousα+ AT 52 (12.1)
Heterozygous α+ AT 186 (43.1)
G6PD deficiency, n (%)
Normal G6PD (G6PD(B)) 263 (84.2)
Hemizygous (G6PD(A-)) 24 (5.6)
Homozygous (G6PD(A-) 4 (0.9)
Heterozygous (G6PD(A)) 40 (9.3)
HbA1c level, mean (SD), (%) 5.7 (1.1)
2-hr glucose level in OGTT mean (SD), (mmol/L) 8.2 (2.4)
HIV, Human Immunodeficiency Virus; ART, antiretroviral therapy; G6PD, glucose-6-phosphate dehydrogenase;
HbA1c, Hemoglobin A1c; OGTT, oral glucose tolerance test.
https://doi.org/10.1371/journal.pone.0244782.t001
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PD/DM diagnosis by HbA1c
Fewer participants with SCT, 22/110 (20.0%), were diagnosed with PD/DM by HbA1c com-
pared to those without SCT, 178/321 (55.5%). There was strong evidence that among partici-
pants with SCT, there was reduced odds of PD/DM diagnosis by HbA1c in both unadjusted
and adjusted analyses (adjusted OR 0.15, 95% CI: 0.08, 0.26) (Table 3). Median HbA1c level
among SCT participants was (5.8% (5.3:6.2) compared to (5.6% (5.1:6.1)) of those without
SCT (S2 Table). The distribution of HbA1c results was shifted downward among those with
SCT compared to those without (Fig 2A).
PD/DM diagnosis by OGTT
The prevalence of PD/DM measured by OGTT in participants with SCT was 60/110 (54.5%)
compared to 151/321 (47.0%) among those without SCT. In contrast to the findings for
HbA1c, there was no evidence that SCT was associated with PD/DM diagnosis by OGTT
(adjusted OR 1.28, 95% CI: 0.82, 2.00) compared to those without SCT (Table 3). There was
also no evidence of a difference in the distributions of OGTT results comparing those with
and without SCT (Fig 3A).
Discriminative ability of HbA1c to Identify PD/DM
Discriminative ability of HbA1c to identify PD/DM was non-significantly lower among partic-
ipants with SCT (AUROC, 0.52; 95% CI, 0.44, 0.59) vs. without SCT (AUROC, 0.57; 95% CI,
0.52, 0.62) when using OGTT-defined PD/DM (p = 0.27, Fig 4). In comparison to the OGTT,
among those with SCT the sensitivity of HbA1c was 21.7% (95% CI: (12.1, 34.2) and specificity
was 82.0% (95% CI: 68.6, 91.4), while among those without SCT, sensitivity was 62.9% (95%
CI: 54.3, 70.2) and specificity was 51.2% (95% CI: 43.4, 58.9) for the diagnosis of PD/DM.
Table 2. Hemoglobin and G6PD deficiency subtypes of the study population (n = 431)1.
Red blood cell polymorphisms Alleles N (%)
No hemoglobinopathy HbAA, no α-thalassemia, G6PD(B) 127 (29.5)
Sickle cell trait (SCT) HbAS, no α-thalassemia, G6PD(B) 38 (8.8)
Homozygous α+ AT HbAA, homozygous α+ AT, G6PD(B) 33 (7.7)
Heterozygous α+ AT HbAA, heterozygous α+ AT, G6PD(B) 110 (25.5)
Homozygous/hemizygous G6PD deficiency2 HbAA, no α-thalassemia, G6PD(A-) 11 (2.6)
SCT, homozygous α+ AT, heterozygous G6PD deficiency HbAA, homozygous α+ AT, G6PD(A) 01 (0.2)
Heterozygous G6PD deficiency HbAA, no α-thalassemia, G6PD(A) 06 (1.4)
SCT, heterozygous α+ AT, heterozygous G6PD deficiency HbAS, heterozygous α+ AT, G6PD(A) 05 (1.2)
SCT, no α-thalassemia, homozygous G6PD deficiency HbAS, no α-thalassemia, G6PD(A-) 04 (0.9)
SCT, homozygous α+ AT, no G6PD deficiency HbAS, homozygous α+ AT, G6PD(B) 11 (2.6)
SCT, no α-thalassemia, heterozygous G6PD deficiency HbAS, no α-thalassemia, G6PD(A) 07 (1.6)
SCT, heterozygous α+ AT, no G6PD deficiency HbAS, heterozygous α+AT, G6PD(B) 44 (10.2)
No SCT, homozygous α+ AT, heterozygous G6PD deficiency HbAA, homozygous α+ AT, G6PD(A) 03 (0.7)
No SCT, heterozygous α+ AT, homozygous G6PD deficiency HbAA, heterozygous α+ AT, G6PD(A-) 09 (2.1)
No SCT, heterozygous α+ AT, heterozygous G6PD deficiency HbAA, heterozygous α+ AT, G6PD(A) 18 (4.0)
No SCT, homozygous α+ AT, homozygous G6PD deficiency HbAA, homozygous α+ AT, G6PD(A-) 04 (1.0)
G6PD; glucose-6-phosphate-dehydrogenase.
1Data are number (%).
2Homozygous is for females while hemizygous is for males.
https://doi.org/10.1371/journal.pone.0244782.t002
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Discussion
In this cross-sectional study among Tanzanian adults with and without HIV, we assessed the
utility of HbA1c for diagnosing diabetes or prediabetes in people with SCT, α-thalassemia, and
G6PD deficiency. SCT was strongly associated with lower values of HbA1c and therefore a
lower prevalence estimate of PD/DM compared to those without SCT. This was not the case
when using OGTT. HbA1c also appeared to underestimate PD/DM in participants with hemi-
zygous or homozygous G6PD deficiency compared to participants without G6PD deficiency.
Our findings of correlation between SCT and HbA1c are only applicable to the HemoCue
HbA1c 501 device and methods used here, as they contrast with other studies’ findings that
used different methods and observed no correlation between SCT and HbA1c. The studies of
Sumner et al and Bleyer et al were conducted in populations with high prevalences of SCT, i.e.,
28% and 21% [6,8], but they combined two different hemoglobin types, i.e., HbAS and HbC
traits, as one group and used different methods for measuring glycated HbA1c which may
Table 3. Association of hemoglobinopathies and G6PD deficiency with prediabetes/diabetes diagnosis by HbA1c and oral glucose tolerance test (OGTT).
PD/DM by HbA1c
Characteristic PD/DM Prevalence, n (%) Crude OR (95% CI)1 P1 Overall P1 Adjusted OR (95% CI)2 P2 Overall P2
Sickle cell trait
No SCT3 178 (55.5) Reference Reference
SCT 22 (20.0) 0.20 (0.12, 0.34) < 0.001 0.15 (0.08, 0.26) < 0.001
α-thalassemia
No α-thalassemia3 83 (43.1) Reference Reference
Homozygous α+ AT 29 (55.8) 1.67 (0.90, 3.10) 0.10 0.25 1.61 (0.82, 3.16) 0.17 0.37
Heterozygous α+ AT 88 (47.3) 1.19 (0.79, 1.78) 0.84 1.17 (0.75, 1.81) 1.81
G6PD deficiency
No G6PD deficiency3 (G6PD (B)) 176 (48.5) Reference Reference
Hemizygous (G6PD (A-)) 8 (33.3) 0.53 (0.22, 1.27) 0.16 0.24 0.40 (0.15, 1.11) 0.08 0.06
Homozygous (G6PD (A-)) 1 (25.0) 0.35 (0.04, 3.44) 0.37 0.19 (0.02, 2.07) 0.17
Heterozygous (G6PD (A)) 15 (37.5) 0.64 (0.33, 1.25) 0.19 0.53 (0.25, 1.14) 0.10
PD/DM by 2-hr OGTT
Sickle cell trait
No SCT3 151 (47.0) Reference Reference
SCT 60 (54.5) 1.35 (0.87, 2.09) 0.18 1.28 (0.82, 2.00) 0.28
α-thalassemia
No α-thalassemia3 89 (46.1) Reference Reference
Homozygous α+ AT 32 (61.5) 1.87 (1.00, 3.50) 0.05 0.14 2.00 (1.04, 3.84) 0.04 0.11
Heterozygous α+ AT 90 (48.4) 1.10 (0.73, 1.64) 0.66 1.15 (0.76, 1.74) 0.51
G6PD deficiency
No G6PD deficiency3 (G6PD (B)) 181 (49.9) Reference Reference
Hemizygous (G6PD (A-)) 16 (66.7) 2.01 (0.84, 4.82) 0.12 0.04 1.81 (0.72, 4.59) 0.21 0.13
Homozygous (G6PD (A-)) 2 (50.0) 1.01 (0.14, 7.21) 1.00 1.26 (1.16, 9.61) 0.83
Heterozygous (G6PD (A)) 12 (30.0) 0.43 (0.21, 0.87) 0.02 0.47 (0.22, 0.99) 0.05
SCT, sickle cell trait; G6PD, glucose-6-phosphate dehydrogenase; PD/DM, prediabetes/diabetes.
1Unadjusted analysis; variables involved in unadjusted analysis were age, sex, socioeconomic status, smoking status, alcohol use, body mass index, HIV status and
hemoglobin level.
2Adjusted for all variables associated with PD/DM by HbA1c or OGTT, with overall p. value of < 0.2 before adjusted. Those variables were age, sex, body mass index,
HIV status and hemoglobin level.
3For each trait, the reference group comprised participants without that specific trait, even though they may have one or both of the other traits investigated.
https://doi.org/10.1371/journal.pone.0244782.t003
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explain the different results. They conducted the analyses with cation exchange column chro-
matography on automated high performance liquid chromatography (HPLC) (VariantII-
Turbo, BioRad Laboratories, Hercules California USA) [6,8], with further confirmation by
Boronate Affinity Chromatography on Premier Hb9210 analyser (Trinity Biotech, Bray, Ire-
land) [6].
Using OGTT, we observed that participants with either homozygous α+ AT or hemizygous
G6PD deficiency trended toward higher prevalence of PD/DM diagnosis compared to those
with no α-thalassemia or G6PD deficiency. The association was not strong and the mechanism
behind it is not well understood, but this finding was also reported in other studies [25,26]. To
further investigate the associations, studies with larger sample sizes should be conducted. To
elucidate mechanisms, clinical and translational research such as glucose/insulin kinetics stud-
ies in people with hemoglobinopathies and G6PD deficiency is required.
Fig 2. A: Boxplots of HbA1c comparing sickle cell trait status. By using HbA1c, 29/52 (55.8%) of participants with
homozygous α+ AT and 88/186 (47.3%) of participants with heterozygous α+ AT had PD/DM, while among those without α-
thalassemia, 83/193 (43.0%) did (Table 3). α-thalassemia was not associated with diagnosis of PD/DM by HbA1c (overall p = 0.37
in the adjusted model, Table 3). However, there was a tendency for increased odds of PD/DM among those with homozygous α-
thalassemia (adjusted OR 1.61, 95% CI: 0.82, 3.16) (Table 3). Median HbA1c level was highest among homozygotes (S2 Table) and
there was an upward shift in the distribution of HbA1c among homozygotes compared to those without α-thalassemia (Fig 2B).
B: Boxplots of HbA1c comparing α-thalassemia status. In participants with G6PD deficiency, 8/24 (32.3%) hemizygous males,
1/4 (25.0%) homozygous female, and 15/40 (37.5%) heterozygous females had PD/DM by HbA1c, compared to 176/363 (48.5%)
of those with no G6PD deficiency (Table 3). Among people with hemizygous or homozygous G6PD deficiency, there was weak
evidence of decreased odds of PD/DM diagnosis by HbA1c compared to those without G6PD deficiency (overall p = 0.06 in
adjusted model Table 3). Compared to those without G6PD deficiency, there was decreased odds of PD/DM in hemizygotes
(adjusted OR 0.40, 95% CI: 0.15, 1.11), homozygotes (adjusted OR 0.19, 95% CI: 0.02, 2.07) and heterozygotes (adjusted OR 0.53,
95% CI: 0.25, 1.14) (Table 3). Median HbA1c was slightly lower in hemizygous, homozygous and heterozygous G6PD deficiency
(S2 Table), and their distributions were shifted down compared to those without G6PD deficiency (Fig 2C). C: Boxplots of
HbA1c comparing G6PD deficiency status. There was no evidence for interaction between HIV status and SCT (p = 0.62),
homozygous or heterozygous α+ AT (p = 0.49), or G6PD deficiency (p = 0.40) with regard to PD/DM diagnosis by HbA1c.
Sensitivity analyses yielded results that were materially similar to those presented here.
https://doi.org/10.1371/journal.pone.0244782.g002
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Our study has a number of strengths. First, samples were randomly selected from stored
blood samples of a large cohort study, CICADA, conducted in Mwanza, northwestern Tanza-
nia, commonly known to have a high prevalence of hemoglobinopathies, especially SCT and
α-thalassemia. This enabled us to assess the hypothesized associations within a modest sample
size. Second, to our knowledge there are very few studies that have examined associations of
HbA1c with SCT, α-thalassemia and G6PD deficiency in a single cohort. Many studies have
established an association of one trait, e.g., SCT, with HbA1c, without considering other traits
that impact red blood cells.
The study also had limitations. First, we included only Tanzanians and found the only
abnormal hemoglobin type to be HbAS. Hemoglobin variants other than HbAS, for which we
did not test, could also potentially affect the validity of HbA1c measurements [4,27]. HbAS is
not the only trait of concern, therefore studies that involve populations of more than one
Fig 3. A: Boxplots of OGTT comparing sickle cell trait status. By OGTT, PD/DM was prevalent in 32/52 (61.5%) of
participants with homozygous α+ AT, 90/186 (48.4%) of those with heterozygous α+ AT, and 89/193 (46.1%) of those without
α-thalassemia (Table 3). Compared to those without α-thalassemia, participants with homozygous α+ AT had increased odds of
being diagnosed with PD/DM by OGTT (adjusted OR 2.00, 95% CI: 1.04, 3.84) (Table 3). However, there was overall no
evidence that α-thalassemia was associated with diabetes diagnosis by OGTT (overall p = 0.11 in adjusted analysis). Compared
to those without α-thalassemia, the median OGTT glucose was highest among homozygotes (S2 Table) and the distributions of
OGTT results were shifted upward among those with homozygous α+ AT (Fig 3B). B: Boxplots of OGTT comparing α-
thalassemia status. Those with hemizygous, homozygous or heterozygous G6PD deficiency had PD/DM prevalence of 16/24
(66.7%), 2/4 (50.0%), and 12/40 (30.0%) respectively, while in those with normal G6PD activity, PD/DM prevalence was 181/
363 (49.9%) (Table 3). Compared to those without G6PD deficiency, heterozygous females had decreased odds of PD/DM
diagnosis (adjusted OR 0.47, 95% CI: 0.22, 0.99, Table 3). Median OGTT glucose was highest among hemizygotes (8.6 (7.4:9.6)
mmol/L) and lowest among heterozygotes (7.5 (6.8:8.0) mmol/L) when compared to those without G6PD deficiency (7.7
(7.0:8.7) mmol/L) (S2 Table). The distribution was shifted upward among hemizygotes while in heterozygotes the distribution
was shifted downward compared to those not deficient (Fig 3C). C: Boxplots of OGTT comparing G6PD deficiency status.
No interaction was observed between HIV status and SCT (p = 0.61), α-thalassemia (p = 0.80), or G6PD deficiency (p = 0.35)
with regard to PD/DM diagnosis by OGTT. Sensitivity analyses were consistent with the presented results.
https://doi.org/10.1371/journal.pone.0244782.g003
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country and different abnormal hemoglobin variants, e.g., HbAC, HbCC, HbSC and HbE are
needed to confirm and complement our findings. Second, validation of these findings with
other HbA1c assays could help to explain the disparate PD/DM prevalence by HbA1c reported
by other investigators in people with SCT, α-thalassemia or G6PD deficiency.
Conclusions
Our findings add to the body of scientific evidence that hemoglobinopathies can influence
diagnosis of PD/DM using HbA1c. Even though our findings relied on a single device, Hemo-
Cue HbA1c 501, we suggest that HbA1c be used and interpreted with caution in areas with
high prevalences of hemoglobinopathies such as sub-Saharan Africa. Economical and cost-
effective screening strategies for hemoglobinopathies and diabetes case management guide-
lines, e.g., instrument-specific glycated HbA1c thresholds for SCT individuals should be con-
sidered. When using OGTT, higher prevalence of PD/DM was recorded among participants
with homozygous α-thalassemia and hemizygous G6PD deficiency cohorts; further larger
scale studies are warranted to investigate these associations.
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